Utah Medical v. Tyco
This article was originally published in The Gray Sheet
Executive Summary
Utah federal appeals court affirms district court's September 2002 permanent injunction against sales of Tyco/Kendall-LTP's 4000 Softrans intrauterine pressure catheter, along with a $23 mil. award to Utah Medical. The latter firm now plans to pursue "additional damages" for "willful" infringement following a January 2002 jury verdict that the Tyco device infringes a Utah Intran Plus IUPC patent (1"The Gray Sheet" Sept. 23, 2002, In Brief)...
You may also be interested in...
Utah Medical Sues FDA For Export Certificates Denied Over GMP Findings
Utah Medical cites FDA's refusal to engage in "meaningful" dialogue about alleged good manufacturing practice deficiencies since 2001 as the origin of a dispute that has yielded two lawsuits against the agency
Utah Medical v. Tyco
Permanent injunction against sales of Tyco/Kendall-LTP's Softrans 4000 intrauterine pressure catheter is issued by Utah federal court, along with $23 mil. in damages and interest to Utah Medical, following a January jury verdict that Tyco infringed a patent related to Utah's Intran Plus IUPC (1"The Gray Sheet" Jan. 21, 2002, In Brief). Utah, which filed suit in 1997, maintains that Tyco group purchasing contracts with Premier and Novation kept the Intran Plus from 70% of the hospital market...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”